Contents of Supplementary Figures and
Oligonucleotides used in miRFLP DILI assay.
Supplementary Table 2
Intra-assay variance of miRFLP DILI assay. Supplementary Table 3 Intra-assay accuracy of miRFLP DILI assay. Supplementary Table 4 Oligonucleotides used in miRFLP hsa-let-7 assay. Supplementary Table 5 Specificity evaluation of miRFLP assay on hsa-let-7 family members. Supplementary Table 6 hsa-let-7 miRNA sequence comparison chart. Supplementary Table 7 Oligonucleotides used in miRFLP miR-92ab assay. Supplementary Table 8 Oligonucleotides used in miRFLP IM assay. Supplementary Table 9 Incubation duration affects the quantification of serum miRNAs. Supplementary Table 10 Optimization of serum-direct miRFLP assay. Supplementary Table 11 Correlation coefficients of tissue-enriched miRNAs and RBCassociated miRNAs in sera of rats over the time course of CCl4 treatment. Supplementary Table 12 The responses of ABI 3730xl DNA analyzer detector. Supplementary Figure 1 The schematic representation of omega primer. A: PCR primer target site. B: size-coding region. The numbers of nucleotides in this region can be edited to change the length of final PCR products. C: Probe region. The nucleotide sequence used here is reverse complimentary to the 3´end of target RNA. D: stem-loop region. The nts fold into a strong stem loop at low temperature to separate probe sequence from other functional regions structurally. The partitioning of functional groups allows independent alteration of nts in probe and size-coding regions. Properly formed omega primers also demonstrate additional features that benefit the priming of short RNAs, such as target location preference on RNA 3´ends, reduced primer dimerization and minimum internal initiation etc (Patent No.: PCT/CN2013/070525). 
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Purified RNA Serum Supplementary Figure 3 The ROC curves of selected miRNAs for diagnosis of bronchopneumonia, bronchiolitis and acute asthmatic bronchiolitis patients. The ROC curves of hsa-miR-181a, hsa-miR-150, hsa-miR-146a, hsa-miR-222 and hsa-miR-146b on their predictive values to differentiate the cohorts of bronchopneumonia, bronchiolitis and acute asthmatic bronchiolitis from other cases were drawn in 1-Specificity plot. The AUC values of tested miRNAs were: hsa-miR-146a (0.877, p < 0.001, 0.820 -0.934), hsa-miR-181a (0.709, p < 0.001, 0.626 -0.793), hsa-miR-150 (0.720, p < 0.001, 0.646 -0.809), hsa-miR-222 (0.753, p < 0.001, 0.673 -0.834) and hsa-miR-146b (0.772, p < 0.001, 0.695 -0.848). Figure 4 The ROC curves of miRNAs for diagnosis of asthma patients. The ROC curves for hsa-miR-181a, hsa-miR-150, hsa-miR-146a, hsa-miR-222 and hsa-miR-146b on their predictive values to differentiate asthma patients from other cases were drawn in 1-Specificity plot.
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The AUC values for tested miRNAs were: hsa-miR-146a (0.775, p < 0.001, 0.701 -0.848), hsa-miR-181a (0.580, p = 0.181, 0.466 -0.694), hsa-miR-150 (0.543, p = 0.476, 0.438 -0.648), hsa-miR-222 (0.477, p = 0.702, 0.369 -0.585) and hsa-miR-146b (0.626, p = 0.035, 0.52 -0.733).
Supplementary Figure 5
The ROC curves of miRNAs for diagnosis of asthma and asthmatic bronchiolitis patients. The ROC curves for hsa-miR-181a, hsa-miR-150, hsa-miR-146a, hsa-miR-222 and hsa-miR-146b on their predictive values to differentiate asthma and asthmatic bronchiolitis patients from other cases were drawn in 1-Specificity plot. The AUC values for tested miRNAs were: hsa-miR-146a (0.820, p < 0.001, 0.753 -0.888), hsa-miR-181a (0.559, p = 0.232, 0.461 -0.657), hsa-miR-150 (0.473, p = 0.591, 0.381 -0.566), hsa-miR-222 (0.487, p = 0.800, 0.392 -0.583) and hsa-miR-146b (0.611, p = 0.047, 0.519 -0.703).
